Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC.
Recruiting
- Conditions
- Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC
- Registration Number
- NCT06327178
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Brief Summary
Prior research has indicated that stereotactic body radiotherapy (SBRT) can effectively trigger systemic anti-tumor immune response. The goal of this observational study is to learn about abscopal effects of stereotactic body radiotherapy and concurrent anti-PD-1 antibody treatment in patients of metastatic clear renal cell carcinoma. The primary objective was to assess the objective response rate (ORR) in non-irradiated lesions, and incidence of adverse events (AEs).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Age≥18 years at the time of signing informed consent;
- Histologically confirmed, advanced renal cell carcinoma of stage IV (AJCC 8);
- Previously received SBRT and concurrent PD-1 blockade treatment；
- Evidence of measurable metastatic kidney cancer according to RECIST 1.1 criteria.
Exclusion Criteria
- Patients who cannot be adequately followed up;
- Has a known additional malignancy that is progressing or requires active treatment.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Objective Response Rate Up to 2 years.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Nanfang Hospital, Southern Medical University
🇨🇳Guangzhou, Guangdong, China